ダウンロード数: 223
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
37_1749.pdf | 527.04 kB | Adobe PDF | 見る/開く |
タイトル: | 尿路感染症に対するニューキノロン系抗菌剤sparnoxacinの臨床的検討 |
その他のタイトル: | Clinical study of sparfloxacin, a new quinolone derivative, on urinary tract infection |
著者: | 鈴木, 恵三 堀場, 優樹 名出, 頼男 篠田, 正幸 日比, 秀夫 置塩, 則彦 柳岡, 正範 長久保, 一朗 |
著者名の別形: | Suzuki, Keizo Horiba, Masaki Naide, Yorio Shinoda, Masayuki Hibi, Hideo Okishio, Norihiko Yanagioka, Masanori Nagakubo, Ichiro |
キーワード: | Sparfloxacin UTI New quinolone |
発行日: | Dec-1991 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 37 |
号: | 12 |
開始ページ: | 1749 |
終了ページ: | 1757 |
抄録: | AUC 22例とCC-UTI 51例に投与した.1) AUC 1日1回100 mg, 3日間投与を主とした結果, UTI判定基準(19例)で100%の有効率(著効率78.9%)をえた.2) CC-UTI 1日1回200~300 mg, 5日間投与ではUTI判定基準(22例)で45.5%の有効率であった.7日間投与(21例)の主治医判定では61.9%の有効率を示した.総合的には55.1%の有効率であった.3) 2例に腎機能に軽い影響を与えた.自他覚的副作用では9例に副作用の発現をみた.このうち投与中止は2例で Sparfloxacin (SPFX) was evaluated for its clinical efficacy in 22 patients with acute uncomplicated cystitis (AUC) and 51 with chronic complicated urinary tract infection (CC-UTI). SPFX was administered in a single oral daily dose of 100 mg for 3 days to the patients with AUC. According to the UTI criteria, the efficacy rate was 100% (excellent rate was 78.9%). SPFX was also administered in a single oral dose of 200 to 300 mg mostly for 5 days to patients with CC-UTI. The efficacy rate according to the UTI criteria in the evaluable 22 cases was 45.5%. The efficacy rate according to the physicians in charge, evaluated as either excellent or good for the 23 cases treated with SPFX for 7 and 14 days was 65.2%, the overall efficacy rate in 49 cases including the administration for 5 days being 55.1%. In safety profile, subjective side effects were observed in 9 cases (12.3%), in 2 of which the medication was discontinued (2.7%). These side effects, flowever, recovered without any treatment to normal at the completion or discontinuation of the medication. The clinical laboratory values showed a slight elevation of BUN in 2 cases. SPFX was the most potent antimicrobial brug with a long blood elimination half life among the existing current new quinolones (NQs), indicating a possibility of once-a-day treatment regimen. In safety, side effects of SPFX were similar in general to those of other current NQs. Thus, SPFX is regarded as a highly useful antimicrobial drug when the drug is administered with consideration for its unique characteristics. |
URI: | http://hdl.handle.net/2433/117402 |
PubMed ID: | 1664649 |
出現コレクション: | Vol.37 No.12 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。